Low albumin combined with low-molecular-weight heparin as risk factors for liver injury using azvudine: Evidence from an analysis of COVID-19 patients in a national prospective pharmacovigilance database

CONCLUSION: This study represents the first investigation of azvudine-induced liver injury and high-risk patients using the CHPS. The findings provide valuable insights to promote the safety of anti-COVID-19 drugs, serving as an important reference for future drug safety measures.PMID:38431833 | DOI:10.5414/CP204544
Source: International Journal of Clinical Pharmacology and Therapeutics - Category: Drugs & Pharmacology Authors: Source Type: research